Our Partners and Collaborations Validating Our Platform

Commercialization

Commercialization

Learn More

CytoSolve® partnered with Wapiti Labs to computationally validate Elk Velvet Antler health benefits, enabling evidence-based commercialization through large-scale systems bioinformatics.

Commercialization

Learn More

CytoSolve® partnered with Alnylam to computationally model HAE contact activation pathways, predicting siRNA target-response relationships and accelerating RNAi therapeutic strategies.

Commercialization

Learn More

CytoSolve® modeled gut motility pathways to mechanistically validate Actazin™ and Livaux™, enabling evidence-based commercialization of digestive health supplements through systems.

Commercialization

Learn More

CytoSolve® enabled British American Tobacco to mechanistically validate relaxation-focused ingredients through systems-level modeling of stress-regulating molecular pathways.

Commercialization

Learn More

CytoSolve enabled Systems Health to translate molecular pathway science into courses, personalized reports, and product experiences via scalable in silico systems architecture.

Commercialization

Learn More

CytoSolve powered VASHIVA’s pathway-based content, validated ingredients in silico, screened combinations, and enabled compliant commercialization of education and products platforms.

Commercialization

Learn More

CytoSolve provided General Interactive a scalable in silico backbone to turn complex biology into validated models, defensible documentation, and market-facing offerings.

Commercialization

Learn More

CytoSolve enabled Life Extension to identify ingredients, integrate validated testosterone pathway models, screen combinations, optimize doses, and advance three formulations toward clinical testing.

Commercialization

Learn More

CytoSolve built an integrative LGCI model, screened FBV phytonutrients for synergy, and produced reproducible, government-ready evidence supporting commercialization and claims.

Commercialization

Learn More

CytoSolve® integrated validated pain-pathway models to quantify apigenin–hesperidin synergy, generating patent-ready evidence across inflammation, nociception, and oxidative stress.

Commercialization

Learn More

CytoSolve® revolutionizes ALS treatment with patient-specific Molecular Digital Twin™, accelerating drug development, validation, and regulatory approval for personalized therapies.